Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
NCT04990778 · M.D. Anderson Cancer Center · PHASE2 · withdrawn · last registry update 2022-03-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI Request” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TP53 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-02Results posted on the registry: Mayo Clinic, Dexamethasone + Idasanutlin (NCT02633059)
- 2022-10-06Also stopped (terminated): Insel Gruppe AG, University Hospital Bern, HDM201 + Midostaurin (NCT04496999)
- 2022-09-29Also stopped (terminated): Novartis Pharmaceuticals, LXS196 + LXS196 and HDM201 (NCT02601378)
- 2022-09-21Results posted on the registry: Aprea Therapeutics, APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) (NCT02098343)
- 2022-07-21Results posted on the registry: Aprea Therapeutics, APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD) (NCT03268382)
- 2022-07-12Results posted on the registry: Aprea Therapeutics, APR-246 + azacitidine + Azacitidine (NCT03745716)
- 2022-06-21Results posted on the registry: Hoffmann-La Roche, Idasanutlin + Cytarabine (NCT03850535)
- 2022-06-21Also stopped (terminated): Hoffmann-La Roche, Idasanutlin + Cytarabine (NCT03850535)
- 2022-01-11Also stopped (terminated): Hoffmann-La Roche, Cytarabine + Idasanutlin (NCT02545283)
- 2021-12-13Also stopped (terminated): Peter MacCallum Cancer Centre, Australia, APR-246 (NCT02999893)
- 2021-12-08Also stopped (terminated): Hoffmann-La Roche, Idasanutlin (NCT03287245)
- 2021-12-07Also stopped (terminated): Hoffmann-La Roche, Idasanutlin + Obinutuzumab (NCT03135262)
- 2021-09-14Results posted on the registry: Hoffmann-La Roche, Cytarabine + Idasanutlin (NCT02545283)
- 2021-08-11Results posted on the registry: Vanderbilt-Ingram Cancer Center, Atezolizumab + Cobimetinib (NCT03566485)
- 2021-08-11Also stopped (terminated): Vanderbilt-Ingram Cancer Center, Atezolizumab + Cobimetinib (NCT03566485)
- 2021-07-27Results posted on the registry: Hoffmann-La Roche, Idasanutlin + Obinutuzumab (NCT03135262)
- 2021-07-16Also stopped (terminated): Quark Pharmaceuticals, teprasiran + Placebo (NCT03510897)
- 2021-05-27Results posted on the registry: Hoffmann-La Roche, Idasanutlin (NCT03287245)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision